Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis

New antibiotics for the treatment of serious infections in intensive care unit patients

(2019) Sebastiano Leone et al.   CURRENT MEDICAL RESEARCH AND OPINION

Imipenemase-producing carbapenem-resistant Enterobacteriaceae transmission in a long-term-care facility during a community-wide multidrug resistant organism outbreak—North Carolina, 2017

(2019) Heather Dubendris et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae

(2019) Basem M. Alraddadi et al.   BMC INFECTIOUS DISEASES

EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS

(2019) Lorenzo Onorato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Emergence and transmission of New Delhi metallo‐beta‐lactamase‐5‐producing Escherichia coli Sequence Type 361 in a Tertiary Hospital in South Korea

(2019) Yumi Park et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August-October 2018: A case report and literature review

(2019) Maria Rosaria Iovene et al.   World Journal of Clinical Cases

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections

(2018) Matt Shirley   DRUGS

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net

(2017) Jean-François Timsit et al.   INTENSIVE CARE MEDICINE

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

(2017) Juan J. Castón et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

First outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Constantine, Algeria

(2015) Gaelle Cuzon et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Correction: Network Meta-Analysis Using R: A Review of Currently Available Automated Packages

(2015)   PLoS One

Network Meta-Analysis Using R: A Review of Currently Available Automated Packages

(2014) Binod Neupane et al.   PLoS One

A graphical tool for locating inconsistency in network meta-analyses

(2013) Ulrike Krahn et al.   BMC Medical Research Methodology

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons

(2013) Jochem König et al.   STATISTICS IN MEDICINE

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

(2011)   CLINICAL INFECTIOUS DISEASES